Healthcare-Neuroscience Analyst Fadia, along with Douglas Lichtman, a tenured professor of law at UCLA (focus is on patent and copyright law), discuss Jazz Pharmaceuticals’ lawsuit against the FDA regarding the approval of Avadel Pharmaceuticals’ (AVDL) Lumryz on an Analyst/Industry conference call to be held on July 10 at 11 am.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AVDL:
- Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Avadel price target raised to $21 from $17.50 at H.C. Wainwright
- Avadel Pharmaceuticals price target raised to $18 from $16 at Craig-Hallum
- Avadel Pharmaceuticals price target raised to $25 from $22 at Oppenheimer
- Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII